

Resource Summary Report

Generated by [dkNET](#) on Jul 30, 2026

Anti-Jak2, phospho (Tyr1007 / Tyr1008) Antibody, Unconjugated

RRID:AB_330403

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3771, RRID:AB_330403

Antibody Information

URL: http://antibodyregistry.org/AB_330403

Proper Citation: Cell Signaling Technology Cat# 3771, RRID:AB_330403

Target Antigen: Jak2, phospho (Tyr1007 / Tyr1008)

Clonality: unknown

Comments: Applications: W, IP. Consolidation on 10/2018: AB_10889738, AB_10891428, AB_330403, AB_330405.

Antibody Name: Anti-Jak2, phospho (Tyr1007 / Tyr1008) Antibody, Unconjugated

Description: This unknown targets Jak2, phospho (Tyr1007 / Tyr1008)

Target Organism: rat, mouse, human

Antibody ID: AB_330403

Vendor: Cell Signaling Technology

Catalog Number: 3771

Record Creation Time: 20250820T045450+0000

Record Last Update: 20250820T201630+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Jak2, phospho (Tyr1007 / Tyr1008) Antibody, Unconjugated.

No alerts have been found for Anti-Jak2, phospho (Tyr1007 / Tyr1008) Antibody, Unconjugated.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 46 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Han J, et al. (2025) FGL2-induced metabolic dysregulation in enteric neural crest cells provides insight into Hirschsprung disease pathogenesis. *iScience*, 28(9), 113423.

Chiu PH, et al. (2025) Therapeutic stress triggers tumor STAT1 acetylation to disarm immunotherapy. *Cell reports. Medicine*, 6(11), 102448.

Wang Z, et al. (2025) Synergistic role of gut-microbial L-ornithine in enhancing ustekinumab efficacy for Crohn's disease. *Cell metabolism*, 37(5), 1089.

Sun B, et al. (2025) A novel compound DBZ alleviates chronic inflammatory pain and anxiety-like behaviors by targeting the JAK2-STAT3 signaling pathway. *The Journal of biological chemistry*, 301(7), 110223.

Ghosh C, et al. (2024) Type I gamma phosphatidylinositol phosphate 5-kinase i5 controls cell sensitivity to interferon. *Developmental cell*.

Cao T, et al. (2024) Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cells. *Cell*, 187(9), 2288.

Zhang J, et al. (2024) Influenza A virus infection activates STAT3 to enhance SREBP2 expression, cholesterol biosynthesis, and virus replication. *iScience*, 27(8), 110424.

Xie Y, et al. (2024) Deciphering the composition and key driver genes of breast invasive micropapillary carcinoma by multi-omics analysis. *iScience*, 27(11), 111178.

Han L, et al. (2024) AhR-STAT3-HO-1/COX-2 signalling pathway may restrict ferroptosis and improve hMSC accumulation and efficacy in mouse liver. *British journal of pharmacology*, 181(1), 125.

Cao J, et al. (2024) Ruxolitinib improves the inflammatory microenvironment, restores glutamate homeostasis, and promotes functional recovery after spinal cord injury. *Neural regeneration research*, 19(11), 2499.

Manoharan J, et al. (2024) Tissue factor binds to and inhibits interferon- γ receptor 1 signaling. *Immunity*, 57(1), 68.

Du T, et al. (2024) Chronic sleep deprivation disturbs energy balance modulated by suprachiasmatic nucleus efferents in mice. *BMC biology*, 22(1), 296.

Milara J, et al. (2024) Targeting IL-11 to reduce fibrocyte circulation and lung accumulation in animal models of pulmonary hypertension-associated lung fibrosis. *British journal of pharmacology*, 181(16), 2991.

Cao W, et al. (2023) Exosomes derived from platelet-rich plasma promote diabetic wound healing via the JAK2/STAT3 pathway. *iScience*, 26(11), 108236.

Ye F, et al. (2023) TGF β Antagonizes IFN γ -Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma. *Cancer research*, 83(13), 2262.

Cheng Y, et al. (2023) High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma. *Cell reports. Medicine*, 4(10), 101214.

Shen X, et al. (2023) cGAS Mediates Inflammation by Polarizing Macrophages to M1 Phenotype via the mTORC1 Pathway. *Journal of immunology (Baltimore, Md. : 1950)*, 210(8), 1098.

Song Z, et al. (2023) Targeting of Annexin A1 in Tumor-associated Macrophages as a therapeutic strategy for hepatocellular carcinoma. *Biochemical pharmacology*, 213, 115612.

Fang Z, et al. (2023) Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis. *Nature communications*, 14(1), 7725.

Gurska LM, et al. (2023) Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(5), 943.